MLSS

Milestone Scientific is a 30-plus-year-old "biomedical technology company" still describing itself as transitioning from R&D to commercial — and the numbers show why the transition never sticks. Revenue has gone nowhere for five years ($10.3M in FY2021 to $8.97M in FY2025, +4.0% YoY), while the company has lost money every single year: -$6.82M, -$8.71M, -$6.93M, -$4.71M and -$5.72M. The FY2025 operating margin is -63.5% and net margin -63.8%. The 71.4% gross margin proves the product economics aren't the problem; the fixed operating cost base is far too large for a $9M revenue base, and the accumulated deficit of -$134M is the cumulative receipt for that math.

The balance sheet is where 'avoid' becomes the only defensible call. Cash fell 65.8% to just $1.11M against operating cash burn of -$2.92M — roughly four months of runway at the current rate. Stockholders' equity was cut in half (-51.8% to $2.81M) while total liabilities rose 26.0%, pushing liabilities/equity to 1.78x and ROE to -203.4%. Shares already grew 2.6% and the 10-K explicitly frames the stock price around 'liquidity position' and 'capital-raising activities' — corporate language for the dilution or emergency financing that this cash position all but guarantees. Tellingly, R&D was slashed 47.7% to $449K, which is cash-preservation behavior, not the investment you'd expect from a company claiming to be scaling a new standard-of-care platform.